JP2012524733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524733A5 JP2012524733A5 JP2012506340A JP2012506340A JP2012524733A5 JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5 JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vaccine
- immunogenic
- antigen
- mycobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900539 | 2009-04-24 | ||
| DKPA200900539 | 2009-04-24 | ||
| PCT/DK2010/000054 WO2010121618A1 (en) | 2009-04-24 | 2010-04-23 | A tuberculosis tb vaccine to prevent reactivation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127000A Division JP6215260B2 (ja) | 2009-04-24 | 2015-06-24 | 再活性化を予防する結核ｔｂワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524733A JP2012524733A (ja) | 2012-10-18 |
| JP2012524733A5 true JP2012524733A5 (enExample) | 2013-06-06 |
| JP5839361B2 JP5839361B2 (ja) | 2016-01-06 |
Family
ID=43010694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506340A Expired - Fee Related JP5839361B2 (ja) | 2009-04-24 | 2010-04-23 | 再活性化を予防する結核ｔｂワクチン |
| JP2015127000A Active JP6215260B2 (ja) | 2009-04-24 | 2015-06-24 | 再活性化を予防する結核ｔｂワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127000A Active JP6215260B2 (ja) | 2009-04-24 | 2015-06-24 | 再活性化を予防する結核ｔｂワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9074001B2 (enExample) |
| EP (1) | EP2421557B1 (enExample) |
| JP (2) | JP5839361B2 (enExample) |
| KR (2) | KR20170072366A (enExample) |
| CN (2) | CN104107425B (enExample) |
| AU (1) | AU2010238943B9 (enExample) |
| BR (1) | BRPI1006452A2 (enExample) |
| CA (1) | CA2759583C (enExample) |
| DK (1) | DK2421557T3 (enExample) |
| ES (1) | ES2714383T3 (enExample) |
| HK (1) | HK1204549A1 (enExample) |
| IL (1) | IL215591A (enExample) |
| MX (2) | MX370744B (enExample) |
| PL (1) | PL2421557T3 (enExample) |
| TR (1) | TR201903223T4 (enExample) |
| WO (1) | WO2010121618A1 (enExample) |
| ZA (1) | ZA201108564B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2457926T1 (sl) | 2005-04-29 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis |
| GB0618127D0 (en) * | 2006-09-14 | 2006-10-25 | Isis Innovation | Biomarker |
| AU2009273130B2 (en) * | 2008-07-25 | 2014-10-16 | Glaxo Group Limited | Novel compositions and methods |
| BRPI0916705A2 (pt) | 2008-07-25 | 2015-11-10 | Glaxo Group Ltd | polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo. |
| PT2315834T (pt) | 2008-07-25 | 2018-08-10 | Glaxosmithkline Biologicals Sa | A proteína rv2386c de tuberculose, composições e as suas utilizações |
| GB0906215D0 (en) | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| UA110103C2 (uk) | 2010-01-27 | 2015-11-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Модифікований туберкульозний антиген |
| CN107296793A (zh) * | 2011-01-04 | 2017-10-27 | 阿尔西维尔法尔玛公司 | 适于治疗或预防结核的脂质体制剂 |
| BR112014017217B1 (pt) | 2012-01-12 | 2023-01-17 | Archivel Farma, S.L | Agente e composição farmacêutica |
| IN2015DN03962A (enExample) | 2012-10-23 | 2015-10-02 | Statens Seruminstitut | |
| WO2014145923A2 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of The Univeristy Of Pennsylvania | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
| DK3084442T3 (da) * | 2013-12-16 | 2021-06-21 | Statens Seruminstitut | Diagnostiske reagenser til forbedret in vivo eller in vitro cellemedieret immunologisk diagnosticering af tuberkulose |
| US10765731B2 (en) * | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| BR112016023778A2 (pt) * | 2014-04-24 | 2017-10-17 | Statens Seruminstitut | proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas |
| CN104151433A (zh) * | 2014-08-11 | 2014-11-19 | 兰州大学 | 一种结核分枝杆菌融合蛋白及其制备方法和应用 |
| CN104225591A (zh) * | 2014-09-15 | 2014-12-24 | 兰州大学 | 一种免疫佐剂及含有该免疫佐剂的疫苗 |
| MX2018014270A (es) * | 2016-05-21 | 2019-02-14 | Infectious Disease Res Inst | Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa. |
| JP2021522245A (ja) | 2018-04-26 | 2021-08-30 | チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | マイコバクテリア抗原組成物および使用方法 |
| CN110423279B (zh) * | 2019-06-20 | 2021-07-27 | 扩增生物科技(北京)有限公司 | 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用 |
| CN115598041B (zh) * | 2021-07-07 | 2025-08-19 | 中国科学院微生物研究所 | 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用 |
| KR102577332B1 (ko) * | 2021-12-29 | 2023-09-11 | 재단법인 오송첨단의료산업진흥재단 | 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물 |
| KR20250082868A (ko) | 2023-11-30 | 2025-06-09 | 서울대학교산학협력단 | 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도 |
| CN117777259B (zh) * | 2024-02-23 | 2024-06-07 | 上海科新生物技术股份有限公司 | 检测结核感染的抗原组合物、试剂盒及其应用 |
| CN120192426B (zh) * | 2025-03-04 | 2025-11-11 | 江西澄实生物科技有限公司 | 一种预防沙门氏菌感染的疫苗及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| US5955077A (en) * | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
| CN1105236A (zh) * | 1993-11-13 | 1995-07-19 | 丛繁滋 | 肺结核防传播及治疗用气雾剂及其制备方法 |
| CN1051234C (zh) * | 1994-04-15 | 2000-04-12 | 焦安国 | 一种治疗结核病的药物 |
| CA2704354A1 (en) | 1995-06-07 | 1996-12-19 | Connaught Laboratories, Inc. | Expression of lipoproteins |
| US6338852B1 (en) * | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
| WO2001004151A2 (en) | 1999-07-13 | 2001-01-18 | Statens Serum Institut | TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY |
| CA2405247A1 (en) | 2000-04-19 | 2001-10-25 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
| GB0030368D0 (en) | 2000-12-13 | 2001-01-24 | Inst Of Molecul & Cell Biology | Dormancy-induced mycobacterium proteins |
| WO2002054072A2 (en) * | 2001-01-08 | 2002-07-11 | Isis Innovation Limited | Assay to determine efficacy of treatment for mycobacterial infection |
| ES2346043T3 (es) | 2002-04-05 | 2010-10-08 | Institut Pasteur | Identificacion de las regiones rd1 y rd5 asociadas con la virulencia que permite el desarrollo de vacunas mejoradas de m. bovis bcg y m. microti. |
| EP1523331B1 (en) | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
| WO2004067718A2 (en) | 2003-01-24 | 2004-08-12 | Emory University | Necrosis-deficient mutants of tuberculosis bacteria |
| EP1781313A4 (en) * | 2004-06-17 | 2009-08-26 | Beckman Coulter Inc | MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE |
| NZ581306A (en) * | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
| NZ560468A (en) | 2005-01-05 | 2010-05-28 | Isis Innovation | Compositions for immunizing against mycobacterium using Ag85A |
| SI2457926T1 (sl) | 2005-04-29 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis |
| CA2836319A1 (en) * | 2005-06-23 | 2006-12-28 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| EP2040745B1 (en) * | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| AU2009273130B2 (en) | 2008-07-25 | 2014-10-16 | Glaxo Group Limited | Novel compositions and methods |
-
2010
- 2010-04-23 KR KR1020177016378A patent/KR20170072366A/ko not_active Ceased
- 2010-04-23 PL PL10766664T patent/PL2421557T3/pl unknown
- 2010-04-23 AU AU2010238943A patent/AU2010238943B9/en not_active Ceased
- 2010-04-23 TR TR2019/03223T patent/TR201903223T4/tr unknown
- 2010-04-23 ES ES10766664T patent/ES2714383T3/es active Active
- 2010-04-23 MX MX2015009347A patent/MX370744B/es unknown
- 2010-04-23 CN CN201410141208.5A patent/CN104107425B/zh not_active Expired - Fee Related
- 2010-04-23 BR BRPI1006452A patent/BRPI1006452A2/pt not_active Application Discontinuation
- 2010-04-23 DK DK10766664.6T patent/DK2421557T3/en active
- 2010-04-23 JP JP2012506340A patent/JP5839361B2/ja not_active Expired - Fee Related
- 2010-04-23 KR KR1020117028104A patent/KR20120014176A/ko not_active Ceased
- 2010-04-23 EP EP10766664.6A patent/EP2421557B1/en active Active
- 2010-04-23 CN CN201080017717.7A patent/CN102413837B/zh not_active Expired - Fee Related
- 2010-04-23 CA CA2759583A patent/CA2759583C/en active Active
- 2010-04-23 US US13/262,914 patent/US9074001B2/en active Active
- 2010-04-23 MX MX2011011186A patent/MX2011011186A/es active IP Right Grant
- 2010-04-23 WO PCT/DK2010/000054 patent/WO2010121618A1/en not_active Ceased
-
2011
- 2011-10-06 IL IL215591A patent/IL215591A/en active IP Right Grant
- 2011-11-22 ZA ZA2011/08564A patent/ZA201108564B/en unknown
-
2012
- 2012-07-11 HK HK15103708.0A patent/HK1204549A1/xx unknown
-
2014
- 2014-12-12 US US14/569,341 patent/US10519202B2/en active Active
-
2015
- 2015-06-24 JP JP2015127000A patent/JP6215260B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6470179B2 (ja) | 結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン | |
| TWI638829B (zh) | 分枝桿菌抗原疫苗 | |
| CA2759583C (en) | A tuberculosis tb vaccine to prevent reactivation | |
| US10004793B2 (en) | M.tuberculosis vaccines | |
| CN110506108B (zh) | 过表达phoP-phoR的重组BCG | |
| CN102180974B (zh) | 一种结核杆菌融合蛋白及其制备方法和应用 | |
| JP2016513078A (ja) | 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン | |
| CN101822829B (zh) | 一种用于结核病预防的重组卡介苗 | |
| CN101451145A (zh) | 基于t细胞表位的结核基因疫苗及其制备方法和应用 | |
| Lu et al. | Immunogenicity and protective efficacy against murine tuberculosis of a prime‐boost regimen with BCG and a DNA vaccine expressing ESAT‐6 and Ag85A fusion protein | |
| Hanif et al. | DNA Vaccine Constructs Expressing Mycobacterium tuberculosis‐Specific Genes Induce Immune Responses | |
| JP2015513314A5 (enExample) | ||
| CN103266119A (zh) | 一种结核杆菌三抗原融合基因疫苗及其制备方法和应用 | |
| Wang et al. | Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B | |
| JP5994127B2 (ja) | 新規な組換えｂｃｇワクチン | |
| CN101455846A (zh) | 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用 | |
| US10406219B2 (en) | Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same | |
| CN111948387B (zh) | 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用 | |
| US9562080B2 (en) | Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine | |
| CN102772795B (zh) | 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用 | |
| CN104371013B (zh) | 牛分枝杆菌cfp-10的迟发型变态反应抗原表位多肽及其应用 | |
| RU2776479C1 (ru) | Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции | |
| CN101248084A (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
| CN1579550A (zh) | 一种结核杆菌核酸疫苗 | |
| Gong et al. | Immune efficacy of OmpH and OmpA DNA vaccines against avian Pasteurella multocida |